Fortitude Family Office’s Arcutis Biotherapeutics ARQT Stock Holding History

Fortitude Family Office’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.26K	Buy	+48	New	+$1.12K	﹤0.01%	1669

Other funds holding ARQT

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

MFA Wealth Services Thousand Oaks, California $167M AUM 20.54% 1-Year Est. Return

Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return

Fortitude Family Office's ARQT Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 48 shares worth $1.26K. The stake represents ﹤0.01% of the portfolio and ranks #1669 among its holdings.

29 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Fortitude Family Office held 48 shares of Arcutis Biotherapeutics worth $1.26K as of Q2 2026.
Arcutis Biotherapeutics was a new Fortitude Family Office position in Q2 2026.
Arcutis Biotherapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1669 holding.
29 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.